Migracap Lite Tablet SR
Images are for reference. Actual packaging may vary.
Propranolol (40mg) + Flunarizine (5mg)
1 units • Other
A valid prescription is required for this medicine.
Haven’t found an alternative? A health advisor can help you understand what to do next.
We haven't found a cheaper matching alternative in our catalogue right now. Our health advisors can help you explore other options.
Active composition
+1 more active ingredient
Propranolol blocks beta-1 and beta-2 adrenergic receptors, resulting in decreased heart rate, myocardial contractility, and overall cardiac output.
Flunarizine acts as a calcium channel blocker, preventing vasodilation and reducing the frequency of migraine attacks.
Medical applications
Migracap Lite Tablet SR is a sustained-release formulation combining the salts propranolol (40mg) and flunarizine (5mg), indicated for the prophylaxis of migraine and cluster headache. Propranolol, a beta-blocker, exhibits its therapeutic effects by reducing the frequency and severity of migraine attacks, while flunarizine, a calcium channel blocker, demonstrates efficacy in preventing migraine and cluster headache recurrences.
The sustained-release technology enables a gradual release of the active ingredients over a prolonged period, providing a consistent therapeutic effect. Migracap Lite Tablet SR is suitable for patients who require prolonged prophylactic therapy. The recommended dose is one tablet twice daily, taken with or without food. Patients with a history of angina pectoris, asthma, or chronic obstructive pulmonary disease, and those with a recent myocardial infarction or cardiac failure should be closely monitored.
The product may cause dizziness, lightheadedness, or headaches, particularly during the initial phase of treatment. Regular monitoring of blood pressure and electrolyte levels is essential.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Side-effect information is not available for this medicine. Please consult your doctor or pharmacist.
Migracap Lite Tablet SR may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Information regarding the use of Migracap Lite Tablet SR during breastfeeding is not available. Please consult your doctor.
Medical Advice
Migracap Lite Tablet SR should be used with caution in patients with kidney disease. Dose adjustment of Migracap Lite Tablet SR may be needed. Please consult your doctor.
Exercise Caution
It is not known whether Migracap Lite Tablet SR alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Migracap Lite Tablet SR should be used with caution in patients with liver disease. Dose adjustment of Migracap Lite Tablet SR may be needed. Please consult your doctor. Regular monitoring of blood pressure is advisable for dose adjustment.
Regular Checkup
0 reviews for Migracap Lite Tablet SR






